Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17683839 | 0.87 | MAPT (0.36) | MAPTTP53P2RY12KDM4EALDH1A1 | |
| SCHEMBL17544716 | 0.87 | GRM2 (0.37) | MAPTTP53P2RY12KDM4EALDH1A1 | |
| SCHEMBL17544982 | 0.80 | HSP90AA1 (0.36) | HSP90AA1HSP90B1MAPTTP53LMNA | |
| SCHEMBL17670341 | 0.79 | HSP90AA1 (0.47) | HSP90AA1HSP90B1TP53LMNAWDR5 | |
| SCHEMBL17544550 | 0.78 | PDE6D (0.38) | MAPTTP53LMNAPOLBGRM2 | |
| SCHEMBL17544576 | 0.78 | TP53 (0.37) | MAPTTP53LMNAPOLBGRM2 | |
| SCHEMBL17670484 | 0.78 | HSP90AA1 (0.44) | HSP90AA1HSP90B1TP53LMNAWDR5 | |
| SCHEMBL17544575 | 0.77 | HSP90B1 (0.53) | HSP90AA1HSP90B1WDR5 | |
| SCHEMBL17549883 | 0.76 | HSP90AA1 (0.44) | HSP90AA1HSP90B1TP53LMNAWDR5 | |
| SCHEMBL17545006 | 0.75 | MAPT (0.41) | MAPTTP53P2RY12LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3186238-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| WO-2016033169-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033169-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | HSP90AA1 820/4885HSP90B1 2301/4885MAPT 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.